Bibliografía del artículo
1. Sedlinsky CE. Fisiología ósea. En: Climaterio (AAPEC), Coordinador: Depiano AE. Editorial Ascune, Bs. As., pp. 455- 461, 2006.
2. Parfitt AM. The cellular basis of bone remodeling. The quantum concept reexamined in the light of recent advances in cell biology of bone. Calcif Tissue Inter 36:535-545, 1984.
3. Siris ES, Millar PD, Barrett-Connors E et al. Identification and fracture outcomes of undiaggnosed bone mineral density in post menopausal women: results from the Nacional Osteoporosis Risk Assessment (NORA) JAMA 286:2815-2822, 2001.
4. Kanis JA, Johnell O, Oden A, Sembo I et al. Long term risk of osteoporotic fracture in Malmo. Osteoporos Inter 11:669-674, 2000.
5. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929-1936, 2002.
6. Blake GM, Fogelman I. Role of dual-energy X-ray absorptiometry in the diagnosis and treatment of osteoporosis. J Clin Densitom 10:102-110, 2007.
7. Kanis JA, Black D, Cooper C et al. A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Inter 13:527-536, 2002.
8. Johnell O, Kanis JA, Johansson M et al. Predictive value of bone mineral density for hip and other fractures. J Bone Miner Res 22:774-783, 2007.
9. Morosano M, Masoni A, Sánchez A. Incidente of hip fracture in the city of Rosario, Argentina. Osteoporos Inter 16:1339-1334, 2005.
10. Hofbauer LC, Heufelder AE. The role of receptor activator of nuclear factor kB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab 85:2355-2363, 2000.
11. Dunstan CR. Osteoprotegerin and osteoprotegerin ligand mediate the local regulation of bone resorption. Endocrinol 10:18-26, 2000.
12. Turner CH, Duncan RL, Pavalko FM. Mechanotransduction: An inevitable process for skeletal maintenance. En: Novel approaches to treatment of osteoporosis. RGG Russell, TM Skerry, U Kollenkirchen (Eds.). Springer- Verlag, Berlín, pp. 157-177, 1998.
13. Canalis E, Mc Carthy TL, Centrella M. Growth factors and cytokines in bone cell metabolism. Ann Rev Med 42:17-24, 1991.
14. Fernández CE, Nilson de Melo NR, Wehba S. Efectos del tratamiento hormonal de reemplazo sobre el metabolismo óseo en mujeres climatéricas. En: Climaterio y envejecimiento. Pérez-López FR (Ed.), Cometa SA, España, pp. 237-248, 1999.
15. Sowers MR, Jannausch M, Mc Connell D et al. Hormone predictors of bone mineral density changes during the menopause transition. J Clin Endocrinol Metab 91:1261-1267, 2006.
16. Martin TJ, Gaddy D. Bone loss goes beyond estrogens. Nat Med 12:612-613, 2006.
17. Baron R. FSH versus estrogen: who's guilty of breaking bones? Cell Metab 3:302-305, 2006.
18. Kanis JA, Burlet N, Cooper C, Delmas PD et al. European guidance for the diagnosis and management of osteoporosis in post menopausal women. Osteoporos Inter 19:397-428, 2008.
19. Man Z. Metodología de estudio por imágines. En: Climaterio (AAPEC) Coordinador: Depiano AE. Editorial Ascune, Bs. As., pp. 484-494, 2006.
20. Raisz S. Screening for osteoporosis. N Engl J Med 353:164-171, 2005.
21. Masoni A, Morosano M, Pezzotto S, Tomat F, Betancour F et al. Constrution of two instruments for the presuntive detection of post menopausal women with low spinal bone mass by means of clinical risk factors. Maturitas 51:314-124, 2005.
22. Tang B, Eslick GD, Nowson C, Smith et al. Use of calcium in combination with vitamin D supplementation to prevent fractures and bone loss in older people: a meta-analysis. Lancet 370:657-666, 2007.
23. Adami S. Vitamine D and response to treatment in post menopausal osteoporosis. Future Rheumatology 3:407-408, 2008.
24. Bonaiuti D, Shea B, Iovine R, Negrini S et al. Exercise for preventing and treating osteoporosis in post menopausal women. Cochrane Database Syst Rev 2002; 3:CD 000333.
25. Myers AH, Young Y, Langlois JA. Prevention of falls in the elderly. Bone 18:87 S-101 S, 1996.
26. Qasem A, Snow V, Owens DK, et al. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guidelines from the American College of Physicians. Ann Inter Med 149:404-415, 2008.
27. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, et al. Reduction of vertebral fracture risk in post menopausal women with osteoporosis trated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637-645, 1999.
28. Stevenson M, Lloyd Jones M, De Negris E, Brewer N et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and tratment of post menopausal osteoporosis. Health Technol Assess 9:1-160, 2005.
29. Anastasilakis A, Goulis D, Avramidis A. Efectos de la teriparatida sobre el ligando del activador del receptor del factor nuclear kB y la osteoprotegerina. European J Endocrinology 158(3):411-415, 2008.